

AKTUELLE STUDIEN | CURRENT TRIALS

Ongoing Clinical Trials in Dermatology and Venereology in Austria

Sponsor | Principal investigator | Contact email | Patient recruitment until

Graz

Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)

Immunocore | Rainer Hofmann-Wellenhof | studien.derma-onko@uniklinikum.kages.at | December 2027

A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Immunocore | Rainer Hofmann-Wellenhof | studien.derma-onko@uniklinikum.kages.at | December 2027

Study of Oral Deucricitabant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema (RAPIDe-3)

Pharvaris | Birger Kränke | clemens.schoeffl@medunigraz.at | March 2026

Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema (RAPIDe-2)

Pharvaris | Birger Kränke | clemens.schoeffl@medunigraz.at | June 2027

A Phase 3b, Open-Label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

Almirall | Franz J. Legat | franz.legat@medunigraz.at | December 2025

A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects with Prurigo Nodularis Who Are Inadequately Controlled on Topical Therapies or not Eligible for Topical Therapies

Amgen | Franz J. Legat | franz.legat@medunigraz.at | December 2025

A Phase 3 Trial of Fianlimab (REGN3767, ANTI-LAG-3) + Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Regeneron Pharmaceuticals, Inc. | Ingrid Wolf | alexandra.rodlaue-kriegl@medunigraz.at | December 2027

Phase II Study of Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in Patients with Locally Advanced/ Metastatic Squamous Cell Carcinoma of the SKIN

Universitätsklinik für Dermatologie und Allergologie Salzburg | Paracelsus Medizinische Privatuniversität | Rainer Hofmann-Wellenhof | studien.derma-onko@uniklinikum.kages.at | December 2027

A Phase 2 and Phase 3 Peri-Operative Trial of Fianlimab (REGN3767, ANTI-LAG-3) + Cemiplimab versus Anti-PD1 alone Pembrolizumab in Patients with Resectable Stage III and IV Melanoma.

Regeneron Pharmaceuticals, Inc. | Teresa Maria Kränke | studien.derma-onko@uniklinikum.kages.at | December 2027

A Multi-Centre, Randomised, Placebo-Controlled, Double-Blind, Parallel-Group Trial to Evaluate Safety and Efficacy of Spesolimab (BI 655130) i.v. in Adult patients with Ulcerative Pyoderma Gangrenosum (PG) Who Require Systemic Therapy

Boehringer-Ingelheim | Peter Wolf | peter.wolf@medunigraz.at | December 2025

Impact of Ultraviolet B Irradiation on Blood Pressure and Its Association with The Gut Microbiome in Patients With Psoriasis, A Pilot Study

Medical University of Graz | Peter Wolf | JohannesNikolaus.Woltsche@uniklinikum.kages.at | April 2026

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

Abbvie | Peter Wolf | martina.praszl-posch@medunigraz.at | July 2025

A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa

Abbvie | Peter Wolf | martina.praszl-posch@medunigraz.at | July 2026

A Phase 3, Open-Label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children from 2 to Less than 12 Years of Age with Moderate to Severe Atopic Dermatitis

Abbvie | Barbara Binder | martina.praszl-posch@medunigraz.at | December 2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis.

INCYTE | Franz J. Legat | franz.legat@medunigraz.at | April 2026

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus Who are Refractory and/or Intolerant to Antimalarial Therapy

AstraZeneca | Wolfgang Salmhofer | martina.praszl-posch@medunigraz.at | December 2026

A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants with Advanced Melanoma

Eikon Therapeutics | Teresa Maria Kränke | studien.derma-onko@uniklinikum.kages.at | n.a.

Innsbruck

Erythropoetische Protoporphyrin (EPP)-SCENESSE Studie CUV-PASS-001 Unbedenklichkeitsstudie | Krankheitsregister-Studie nach der Zulassung zur Gewinnung von Daten zur Langzeitsicherheit und klinischen Wirksamkeit von SCENESSE (Afamelanotid 16 mg) bei Patienten mit erythropoetischer Protoporphyrin

Clinuvel | Robert Gruber | robert.gruber@tirol-kliniken.at | n.a.

Eine multizentrische, randomisierte, doppelblinde, Phase-I/II-Studie mit Placebokontrolle bei erstmaliger Anwendung am Menschen (first-in-human) und Nachweis des Konzepts zur Bewertung der Sicherheit und Wirksamkeit von topisch angewendeter SXR1096-Creme bei Patienten mit Netherton-Syndrom

Sixera Pharma | Robert Gruber | robert.gruber@tirol-kliniken.at | n.a.

Plattenepithelkarzinomstudie – NIVOSQUACS Studie NIVOSQUACS-CA209-587 Eine Phase II-Studie zu Nivolumab und Relatlimab bei Patienten mit vorbehandeltem, lokal fortgeschrittenem /metastasierendem Plattenepithelkarzinom der Haut

PMU Salzburg | Van Anh Ngyuen | van.nguyen@i-med.ac.at | Dezember 2026

Melanom-Phase-III-Studie von REGENERON R3767-ONC-2011 mit Fianlimab REGN3767, Anti-LAG-3-Antikörper plus Cemiplimab versus Pembrolizumab bei Patienten mit zuvor unbehandeltem irresektablem lokal fortgeschrittenem oder metastasiertem Melanom

Regeneron Pharmaceuticals, Inc. | Van Anh Nguyen | van.nguyen@i-med.ac.at | n.a.

Melanom Phase II/III-Studie von REGENERON R3767-ONC-2208: eine perioperative Phase-II- und III-Studie mit Fianlimab REGN3767 und Cemiplimab im Vergleich zu Anti-PD1 allein bei Patienten mit resektablem Melanom im Stadium III und IV

Regeneron Pharmaceuticals, Inc. | Van Anh Nguyen | van.nguyen@i-med.ac.at | n.a.

Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Phase-III-Studie zur Beurteilung der Wirksamkeit und Sicherheit von Anifrolumab bei Erwachsenen mit chronisch und/oder subakut kutanem Lupus erythematoses, die nicht auf eine Malariatherapie ansprechen oder diese nicht vertragen

AstraZeneca | Barbara Böckle | barbara.boeckle@i-med.ac.at | n.a.

Studie zur Beurteilung der Wirksamkeit der Behandlung mit Anifrolumab im medizinischen Alltag – Multinationale Beobachtungsstudie nach Markteinführung zur Wirksamkeit bei SLE-Patienten, die Anifrolumab im Rahmen der klinischen Standardversorgung erhalten

AstraZeneca | Barbara Böckle | barbara.boeckle@i-med.ac.at | n.a.

Prospektive Validierung eines neuen Biochips zur Diagnostik blasenbildender Autoimmunerkrankungen

Med Uni Innsbruck | Barbara Böckle | barbara.boeckle@i-med.ac.at | n.a.

Hormon-Spiegel und Allergiemarkermessung bei Patienten mit (V.a.) Allergie/allergischer Diathese Kurztitel: „Diagnose- und Prognoseparameter bei allergologischen Erkrankungen“

Med Uni Innsbruck | Paul Bellmann, Moosbrugger-Martinz | paul.bellmann@i-med.ac.at, verena.martinz@i-med.ac.at | n.a.

Social Derma: Eine Fragebogenstudie zur Evaluierung des Einflusses von Sozialen Medien auf Hautgesundheit, Hautvorsorge und Hautpflege

Med Uni Innsbruck | Maximilian Lammer, Matthias Schmuth | maximilian.lammer@i-med.at, matthias.schmuth@i-med.ac.at | n.a.

„Real-world“ klinische Endpunkte bei Patienten mit Merkelzellkarzinom, die in Österreich mit Avelumab behandelt wurden: eine retrospektive Multicenter-Studie

Med Uni Innsbruck | Maximilian Lammer, Van Anh Nguyen | maximilian.lammer@i-med.ac.at, van.nguyen@i-med.ac.at | n.a.

Salzburg

A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Immunocore | Peter Kölblinger | p.koelblinger@salk.at | n.a.

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) (EBSshield)

TWi Biotechnology, Inc | Martin Laimer | m.laimer@salk.at | Q2/Q3 2025

A Phase II, Open Study to Assess Efficacy and Safety of Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa-associated Locally Advanced/Metastatic Squamous Cell Carcinoma

EB-Haus Austria, Universitätsklinik für Dermatologie und Allergologie Salzburg Landeskliniken (SALK) | Johann Bauer | joh.bauer@salk.at | closed

European, Multicenter, Prospective Observational Phase IV Clinical Study to Assess the Impact of Lebrikizumab on Health-Related Well-being and Control of Skin Manifestations in Patients With Moderate-to-Severe Atopic Dermatitis (ADTrust)

Almirall | Damian Meyersburg | d.meyersburg@salk.at | n.a.

EPIK-P4: A Phase II Single Arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients with PIK3CA-Related Overgrowth Spectrum (PROS)

Novartis | Christine Wagger | c.wagger@salk.at | n.a.

Investigator sponsored Trial (BMS) NIVOSQUACS (CA209-587) (akademische Eigenstudie): Phase II Study of Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in Patients with Locally Advanced/ Metastatic Squamous Cell Carcinoma of the SKIN

PMU Salzburg | Martin Laimer | m.laimer@salk.at | Dezember 2026

A Multi-centre, Randomised, Placebo-controlled, Double-blind, Parallelgroup Trial to Evaluate Safety and Efficacy of Spesolimab (BI 655130) i.v. in Adult Patients with Ulcerative Pyoderma Gangrenosum who require Systemic Therapy (1368-0140)

Böhringer-Ingelheim | Martin Laimer | m.laimer@salk.at | n.a.

Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children from 2 to Less Than 12 Years of Age with Moderate to Severe Atopic Dermatitis (Start Up)

Abbvie | Christine Wagger | c.wagger@salk.at | Dezember 2026

Wien

A Phase 3, Randomised, Placebo-controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa who have failed Anti-TNF-therapy

Abbvie | Constanze Jonak | constanze.jonak@meduniwien.ac.at | currently no timeline

Czatch-Genital-PsO: Effectiveness and Safety of Tildrakizumab in the Treatment of Genital Psoriasis in Austria, Switzerland and the Czech Republic

Allmiral | Constanze Jonak | constanze.jonak@medunwien.ac.at | April 2025

Selective Treatment of Oral Povorcitinib in Hidradenitis Suppurativa Long-Term-Extension Study (STOP-HS LTE). A Phase 3, Double-Blind Study to Evaluate the Long-Term-Safety and Efficacy of Povorcitinib in Participants with Moderate to Severe Hidradenitis Suppurativa

Incyte | Constanze Jonak | constanze.jonak@meduniwien.ac.at | May 2025

A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

Alumis Inc. | Paul Sator | Paul.Sator@gesundheitsverbund.at | May 2025

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants with Prurigo Nodularis

ICON plc | Paul Sator | Paul.Sator@gesundheitsverbund.at | June 2027

A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus Who Are Refractory and/or Intolerant to Antimalarial Therapy

AstraZeneca | Christian Posch | christian.posch@gesundheitsverbund.at | competitive

The list contains only trials which are open for patient enrollment. The deadline of notification for the next issue of SKIN is May 15, 2026

Please email your study to: editors@skinonline.at

Die Liste enthält nur Studien, die für die Patientenrekrutierung offen sind. Der Meldeschluss für die nächste Ausgabe von SKIN ist der 15. Mai 2026.

Bitte senden Sie Ihre Studie per E-Mail an: editors@skinonline.at